At Diagnosis
Genomic profiling from blood when tissue is scarce, inaccessible or slow to process. 517 genes with MSI and TMB, in 10 to 14 days.
Whole-Cell Liquid Biopsy
Comprehensive Tumor Mutational Profiling From Whole Cancer Cells
Unlike ctDNA tests, CellSight™ DNA analyzes intact circulating tumor cells. One blood draw gives you the genomic profile and the cells it came from.
517
Genes profiled from intact tumor cells
>99%
Analytical sensitivity for single nucleotide variants
10 to 14
Days from specimen receipt to report
CLIA
Certified laboratory, Jupiter, Florida
Built for the Decisions You Make
CellSight™ DNA is designed for oncologists who need genomic answers when tissue is limited, exhausted or too risky to obtain again.
At Progression
Detect resistance mutations to guide the next therapy with fewer repeat invasive procedures.
When Tissue Biopsy Isn't Feasible
A noninvasive route to genomic information for patients with high-risk comorbidities or deep tumor sites.
Why Whole Cells Matter
Cell-free DNA is a mixture of short, degraded fragments shed by tumor cells, normal cells and blood cells. A circulating tumor cell is the tumor itself, intact and in circulation.
Analyzing intact cancer cells preserves tumor context, captures heterogeneity and keeps the complete genetic material together. Each variant is called from tumor-derived DNA rather than inferred from a dilute fraction, which supports clearer interpretation of copy number changes and tumor mutational burden.
We report CTC counts for every accession alongside the genomic findings, giving you a view of tumor cells in circulation at the time of the draw.
CellSight™ DNA Capabilities
Every result is built on validated outputs. We do not report what we have not validated.
Whole Cancer Cell Isolation
Proprietary, patent-pending enrichment captures rare tumor cells, including in low-burden patients, with CTC counts reported for the full accession.
Genomic Profiling
Next-generation sequencing of 517 cancer-relevant genes: SNVs, indels and copy number variants, plus TMB and MSI status.
Serial Monitoring
Noninvasive and repeatable. Compare CTC counts and genomic findings across time points without another biopsy.
Our Process
A standard specimen workflow with a dedicated preservation tube. Results are typically returned in 10 to 14 days from specimen receipt.
Sample Collection
Two 10 mL CellSave CTC Preservation Tubes of peripheral whole blood, supplied in the CellSight™ DNA kit.
Whole Cancer Cell Isolation
Circulating tumor cells are enriched by negative selection using our proprietary isolation method.
Cell Identification
Candidate tumor cells are identified and enumerated for the accession.
Genomic Profiling
DNA from the isolated cells is sequenced across the panel.
Reporting
A clear, structured clinical report with SNVs, indels, CNVs, TMB, MSI and CTC count, delivered through the Client Portal in 10 to 14 days.
Next Steps
Findings support therapy selection, monitoring at progression and clinical trial enrollment.
Supporting patients and the providers who care for them
Providers get decision-grade genomic information when tissue is scarce. Patients get answers from a blood draw instead of another procedure.
See What a CellSight™ DNA Report Looks Like